rBIO's biosimilar insulin, R-biolin, achieves bioequivalence to Novo Nordisk Novolin® R in animal studies; company prepares for 50x scale-up and readies for in-human studies HOUSTON, Feb. 4, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback